S&P 500   5,123.41
DOW   37,983.24
QQQ   441.74
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.74
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.74
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
S&P 500   5,123.41
DOW   37,983.24
QQQ   441.74
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Wall Street gains ahead of earnings, oil falls as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
Did You Miss the Gold Rush? Try These 2 Silver Stocks
NASDAQ:RXST

RxSight (RXST) Stock Price, News & Analysis

$55.60
+0.52 (+0.94%)
(As of 08:00 AM ET)
Today's Range
$55.60
$55.60
50-Day Range
$46.20
$57.92
52-Week Range
$17.00
$58.21
Volume
463 shs
Average Volume
438,686 shs
Market Capitalization
$2.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.63

RxSight MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.9% Downside
$49.63 Price Target
Short Interest
Healthy
4.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of RxSight in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$7.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

728th out of 928 stocks

Ophthalmic Goods Industry

6th out of 7 stocks

RXST stock logo

About RxSight Stock (NASDAQ:RXST)

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RXST Stock Price History

RXST Stock News Headlines

Bitcoin’s All Time High Is Just the Beginning
Bitcoin has officially hit a new all-time high. But if you think you’re too late… Think again.
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) Stock Price Up 3.4%
RxSight (NASDAQ:RXST) Shares Up 3.4%
Bitcoin’s All Time High Is Just the Beginning
Bitcoin has officially hit a new all-time high. But if you think you’re too late… Think again.
RxSight Inc RXST
RXST Mar 2024 70.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on RxSight (RXST)
Oppenheimer Reaffirms Their Buy Rating on RxSight (RXST)
Forecasting The Future: 9 Analyst Projections For RxSight
Recap: RxSight Q4 Earnings
See More Headlines
Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/15/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Current Symbol
NASDAQ:RXST
Fax
N/A
Employees
374
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.63
High Stock Price Target
$64.00
Low Stock Price Target
$32.00
Potential Upside/Downside
-9.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-48,610,000.00
Pretax Margin
-54.55%

Debt

Sales & Book Value

Annual Sales
$89.08 million
Book Value
$4.47 per share

Miscellaneous

Free Float
29,172,000
Market Cap
$2.04 billion
Optionable
Optionable
Beta
1.22
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Ronald M. Kurtz M.D. (Age 61)
    President, CEO & Director
    Comp: $1.03M
  • Ms. Shelley B. Thunen (Age 70)
    Chief Financial Officer
    Comp: $651.36k
  • Dr. Ilya Goldshleger Ph.D. (Age 49)
    Chief Operating Officer
    Comp: $657.81k
  • Mr. Eric J. Weinberg (Age 63)
    Chief Commercial Officer
    Comp: $638.9k
  • Ms. Rebecca Williston
    Vice President of Accounting & Finance
  • Mr. Matt Haller Ph.D.
    Chief Technology Officer
  • Alex Huang
    Investor Relations
  • Mr. Roy Freeman
    Vice President of Marketing
  • Ms. Caroline Vaughn
    Vice President of Human Resources
  • Mr. Scott Gaines
    Senior VP of Commercial Operations & Business Process

RXST Stock Analysis - Frequently Asked Questions

Should I buy or sell RxSight stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RXST shares.
View RXST analyst ratings
or view top-rated stocks.

What is RxSight's stock price target for 2024?

6 brokerages have issued 1 year target prices for RxSight's shares. Their RXST share price targets range from $32.00 to $64.00. On average, they anticipate the company's stock price to reach $49.63 in the next year. This suggests that the stock has a possible downside of 9.9%.
View analysts price targets for RXST
or view top-rated stocks among Wall Street analysts.

How have RXST shares performed in 2024?

RxSight's stock was trading at $40.32 at the beginning of the year. Since then, RXST shares have increased by 36.6% and is now trading at $55.08.
View the best growth stocks for 2024 here
.

When is RxSight's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RXST earnings forecast
.

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.10. The firm earned $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative net margin of 54.57% and a negative trailing twelve-month return on equity of 31.16%.

What ETF holds RxSight's stock?

iShares Micro-Cap ETF holds 62,576 shares of RXST stock, representing 0.39% of its portfolio.

What guidance has RxSight issued on next quarter's earnings?

RxSight updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.0 million-$135.0 million, compared to the consensus revenue estimate of $128.6 million.

When did RxSight IPO?

RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

Who are RxSight's major shareholders?

RxSight's stock is owned by a number of retail and institutional investors. Top institutional investors include MCIA Inc (0.02%). Insiders that own company stock include Bakker Juliet Tammenoms, Eric Weinberg, Ilya Goldshleger, Jesse Anderson Corley, Robert Keith Warner, Ronald M Md Kurtz, Shelley B Thunen, Shweta Maniar and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RXST) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners